317 related articles for article (PubMed ID: 17562807)
1. Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
Adams DA; Riggs MM; Donskey CJ
Antimicrob Agents Chemother; 2007 Aug; 51(8):2674-8. PubMed ID: 17562807
[TBL] [Abstract][Full Text] [Related]
2. Effect of antibiotic treatment on growth of and toxin production by Clostridium difficile in the cecal contents of mice.
Pultz NJ; Donskey CJ
Antimicrob Agents Chemother; 2005 Aug; 49(8):3529-32. PubMed ID: 16048976
[TBL] [Abstract][Full Text] [Related]
3. Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive Clostridium difficile.
Drudy D; Harnedy N; Fanning S; Hannan M; Kyne L
Infect Control Hosp Epidemiol; 2007 Aug; 28(8):932-40. PubMed ID: 17620240
[TBL] [Abstract][Full Text] [Related]
4. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile.
Drudy D; Quinn T; O'Mahony R; Kyne L; O'Gaora P; Fanning S
J Antimicrob Chemother; 2006 Dec; 58(6):1264-7. PubMed ID: 17018563
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility of hamsters to infection by historic and epidemic BI Clostridium difficile strains during daily administration of three fluoroquinolones.
Phillips ST; Nagaro K; Sambol SP; Johnson S; Gerding DN
Anaerobe; 2011 Aug; 17(4):166-9. PubMed ID: 21511046
[TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Québec, Canada.
Bourgault AM; Lamothe F; Loo VG; Poirier L;
Antimicrob Agents Chemother; 2006 Oct; 50(10):3473-5. PubMed ID: 17005836
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Clostridium difficile-associated diarrhea with a drug formulary change in preferred fluoroquinolones.
Walbrown MA; Aspinall SL; Bayliss NK; Stone RA; Cunningham F; Squier CL; Good CB
J Manag Care Pharm; 2008; 14(1):34-40. PubMed ID: 18240880
[TBL] [Abstract][Full Text] [Related]
8. PCR ribotype prevalence and molecular basis of macrolide-lincosamide-streptogramin B (MLSB) and fluoroquinolone resistance in Irish clinical Clostridium difficile isolates.
Solomon K; Fanning S; McDermott S; Murray S; Scott L; Martin A; Skally M; Burns K; Kuijper E; Fitzpatrick F; Fenelon L; Kyne L
J Antimicrob Chemother; 2011 Sep; 66(9):1976-82. PubMed ID: 21712239
[TBL] [Abstract][Full Text] [Related]
9. Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones.
Dalhoff A; Schubert S
Int J Antimicrob Agents; 2010 Sep; 36(3):216-21. PubMed ID: 20630710
[TBL] [Abstract][Full Text] [Related]
10. Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain.
Biller P; Shank B; Lind L; Brennan M; Tkatch L; Killgore G; Thompson A; McDonald LC
Infect Control Hosp Epidemiol; 2007 Feb; 28(2):198-201. PubMed ID: 17265402
[TBL] [Abstract][Full Text] [Related]
11. [Epidemiological study of Clostridium difficile strains isolated in Jean-Verdier-René-Muret hospitals from 2001 to 2007].
Poilane I; Fantinato C; Cruaud P; Collignon A
Pathol Biol (Paris); 2008; 56(7-8):412-6. PubMed ID: 18842360
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial-associated risk factors for Clostridium difficile infection.
Owens RC; Donskey CJ; Gaynes RP; Loo VG; Muto CA
Clin Infect Dis; 2008 Jan; 46 Suppl 1():S19-31. PubMed ID: 18177218
[TBL] [Abstract][Full Text] [Related]
13. A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile.
Kazakova SV; Ware K; Baughman B; Bilukha O; Paradis A; Sears S; Thompson A; Jensen B; Wiggs L; Bessette J; Martin J; Clukey J; Gensheimer K; Killgore G; McDonald LC
Arch Intern Med; 2006 Dec 11-25; 166(22):2518-24. PubMed ID: 17159019
[TBL] [Abstract][Full Text] [Related]
14. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
[TBL] [Abstract][Full Text] [Related]
15. [Current data and trends on the development of antibiotic resistance of Clostridium difficile].
von Müller L; Halfmann A; Herrmann M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 Nov; 55(11-12):1410-7. PubMed ID: 23114440
[TBL] [Abstract][Full Text] [Related]
16. Clostridium difficile and the disease it causes.
Norén T
Methods Mol Biol; 2010; 646():9-35. PubMed ID: 20597000
[TBL] [Abstract][Full Text] [Related]
17. Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
Spigaglia P; Barbanti F; Louie T; Barbut F; Mastrantonio P
Antimicrob Agents Chemother; 2009 Jun; 53(6):2463-8. PubMed ID: 19364867
[TBL] [Abstract][Full Text] [Related]
18. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model.
Freeman J; Baines SD; Saxton K; Wilcox MH
J Antimicrob Chemother; 2007 Jul; 60(1):83-91. PubMed ID: 17483547
[TBL] [Abstract][Full Text] [Related]
19. Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA.
Ackermann G; Tang YJ; Kueper R; Heisig P; Rodloff AC; Silva J; Cohen SH
Antimicrob Agents Chemother; 2001 Aug; 45(8):2348-53. PubMed ID: 11451695
[TBL] [Abstract][Full Text] [Related]
20. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
